GLP-1受体激动剂对胃肠功能和症状的影响
Rosita D Frazier1, William L Hasler1
1Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, AZ, USA.
Expert review of gastroenterology & hepatology
|October 25, 2025
概括
类似葡萄糖-1受体激动剂 (GLP-1RAs) 影响胃肠功能,可能导致像延迟胃排空等不良事件. 需要基于证据的管理策略来解决这些GLP-1RA副作用.
科学领域:
- 胃肠道学和内分泌学
- 基于英克雷丁的疗法的药理学
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 越来越多地用于糖尿病,肥胖和肝脏疾病.
- 与GLP-1RAs相关的不良事件随着广泛使用而变得越来越明显.
- GLP-1RAs影响胃肠道 (GI) 生理学,导致潜在的并发症.
研究的目的:
- 审查GLP-1RAs对肠道功能,运动性和相关症状的影响.
- 讨论肠外并发症,如胆道疾病和胰腺炎.
- 评估GLP-1RA诱导的不良事件的当前管理策略.
主要方法:
- 在PubMed和EMBASE数据库中进行了全面的文献搜索 (1987年7月至2025年8月).
- 分析详细介绍GLP-1RA对胃肠道过境,运动和症状的影响的研究.
- 审查报告的肠外并发症和管理方法.
主要成果:
- GLP-1RAs可能会损害胃肠道过渡和运动能力,导致症状.
- 胃中食物的保留是令人担忧的,增加了麻醉期间肺吸收的风险.
- 目前对不良事件的管理建议缺乏强有力的基于证据的支持.
结论:
- GLP-1RAs显著影响肠道功能,需要对患者进行仔细监测.
- 进一步的前性,多中心研究对于开发基于证据的GLP-1RA诱导的GI问题管理协议至关重要.
- 新的基于印克雷丁的药物可能具有类似的不良事件概况.
相关概念视频
Glucagon-like Receptor Agonists
840
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
840
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
522
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
522
Dipeptidyl Peptidase 4 Inhibitors
581
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
581
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
880
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
880
Oral Hypoglycemic Agents: Glinides
595
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
595
Oral Hypoglycemic Agents: Biguanides and Glitazones
582
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
582


